Invenio Imaging Completes Patient Enrollment in Pivotal AI Study for Lung Cancer Detection

Invenio Imaging, an industry leader in the realms of fresh tissue imaging and artificial intelligence, has proudly announced the completion of patient enrollment in its transformative ON-SITE study. This pivotal research aims to assess the efficacy of the NIO® Lung Cancer Reveal, an AI-driven image analysis module designed for the swift evaluation of bronchoscopic lung biopsy specimens.

Overview of the ON-SITE Study

The ON-SITE study represents one of the most extensive prospective multicenter trials in the field of interventional pulmonology. It involved the enrollment of 1,006 patients spanning seven medical centers and engaged an impressive roster of 32 physicians. Throughout the study, over 3,250 fresh biopsy specimens were collected using various methods, including transbronchial forceps biopsy, cryobiopsy, transbronchial needle aspiration, and endobronchial ultrasound-guided transbronchial needle aspiration.

Jay Trautman, PhD, co-founder and CEO of Invenio Imaging, expressed his gratitude, stating, "Completing enrollment in ON-SITE is a major milestone for Invenio and for our Lung Cancer Reveal program. We're incredibly thankful to everyone involved—from the patients to the clinical research teams. Their commitment has made a clinical effort of this magnitude possible and has advanced us closer to delivering rapid, AI-enabled tissue assessments directly in the bronchoscopy room."

The Challenge of Accurate Diagnosis

While advancements in bronchoscopy have been remarkable, one substantial hurdle persists: accurately determining whether a biopsy provides the necessary tissue for diagnosis during the procedure. Rapid on-site evaluation (ROSE) can offer immediate insights, yet this process demands specialized pathology personnel, which is often not readily available. Dr. Gustavo Cumbo-Nacheli, an interventional pulmonologist and a lead investigator in the ON-SITE study, commented, "As bronchoscopic techniques evolve, our ability to evaluate collected tissue during procedures has not kept up. There is a pressing clinical need for swift feedback, enabling physicians to assess tissue within the procedure suite. An effective in-room tissue assessment approach could significantly streamline bronchoscopy workflows."

The NIO® Imaging System rises to meet this challenge by rapidly imaging fresh, unprocessed biopsy tissue without traditional processes like freezing, sectioning, or staining. Importantly, it preserves the specimen for further pathology and molecular analysis, enhancing its utility for comprehensive diagnostic evaluations.

Dr. George Cheng, another principal investigator involved in the ON-SITE study, emphasized the collaborative spirit of the research teams across the participating medical centers. He noted, "The scale of ON-SITE is impressive and illustrates a remarkable collaborative effort. We worked diligently to enroll patients and acquire thousands of specimens across multiple bronchoscopic biopsy techniques. It’s gratifying to be part of such an ambitious prospective study that could redefine diagnostic standards."

Looking Ahead

The NIO® Lung Cancer Reveal recently received FDA Breakthrough Device Designation, which signifies its intended use as a resource for assisting medical professionals in the evaluation of bronchoscopic lung forceps biopsies. This innovative system is designed to detect cellular and tissue morphologies indicative of cancer by analyzing the images acquired from fresh, unprocessed biopsy specimens. However, it's crucial to note that this AI-driven output should serve as a complementary tool, not as a primary diagnostic solution; physicians are urged to consider all clinical factors before making decisions.

As Invenio Imaging prepares for regulatory submission, the data obtained from the ON-SITE study will play a critical role in reinforcing the validity of its claims and effectiveness. Currently, the NIO® Lung Cancer Reveal remains investigational within the United States and has yet to be authorized for clinical usage.

Invenio Imaging continues its mission to enhance cancer care through the integration of cutting-edge technology and intelligence, with its first AI innovation, the NIO® Glioma Reveal, already CE-marked and utilized clinically in Europe.

Supported by the National Cancer Institute under Award Number 1R44CA281581-01, the ON-SITE study's findings will be instrumental in shaping future diagnostics and therapeutic strategies in lung cancer management.